4552 — JCR Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- ¥64bn
- ¥109bn
- ¥40bn
Brief: Jcr Pharmaceuticals Co Ltd Jcr Announces Achievement Of Milestone Using J-Brain Cargo Technology For Neurodegenerative Disease In Research Collaboration With Alexion
Table: Jcr Pharmaceuticals - 9-MTH group results
Brief: Jcr Pharmaceuticals And Takeda Pharmaceuticals Announce Discontinuation Of Gene Therapy Collaboration
Brief: Jcr Announces Research Collaboration, Option And License Agreement With Alexion
Brief: JCR Pharmaceuticals Co Ltd And Takeda Pharmaceuticals Announce Discontinuation Of Gene Therapy Collaboration
Brief: JCR Pharmaceuticals Co Ltd Announces Research Collaboration, Option And License Agreement With Alexion On Discovery Of Oligonucleotide Therapeutics Using J-Brain Cargo
Brief: U.S. FDA Grants Orphan Drug Designation To Jr-441 For The Treatment Of Mucopolysaccharidosis Type Iiia (Mps Iiia)
Brief: JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
Table: Jcr Pharmaceuticals - 6-MTH group results
Announces 52-Week Interim Data From Its Global Phase I/II Study Of JR-171 In Individuals With MPS I
Table: Jcr Pharmaceuticals -2023/24 group forecast
Table: Jcr Pharmaceuticals -Q1 group results
Brief: Jcr Pharmaceuticals Receives Approval To Start Global Phase I/Ii Clinical Trial For Jr-441 For Treatment Of Mucopolysaccharidosis Type Iii A
Italy's Angelini invests up to $506 mln in Japan's JCR for epilepsy drug (updated)
Brief: Angelini Pharma And Jcr Pharmaceuticals Announce Global Collaboration For The Development And Commercialization Of Novel Biologic Therapies In Epilepsy
Italy's Angelini invests up to $506 mln in Japan's JCR for epilepsy drug
Angelini Pharma And JCR Announce Global Collaboration For Development And Commercialization Of Novel Biologic Therapies In Epilepsy
Table: Jcr Pharmaceuticals -2022/23 parent results
Table: Jcr Pharmaceuticals -2022/23 group results